Q3 EPS Estimates for HealthEquity Boosted by Analyst

Key Points

• Analysts at Barrington Research have increased their Q3 2026 earnings per share (EPS) estimate for HealthEquity to $0.73, up from $0.72, with a price target set at $125.00 and an "Outperform" rating.
• Several firms, including Bank of America and Jefferies Financial Group, have raised their target prices for HealthEquity, indicating a positive outlook, with the average target price now at $119.77.
• Institutional investors own 99.55% of HealthEquity, with significant stakes being increased by firms such as Invesco and Westfield Capital Management.

HealthEquity, Inc. (NASDAQ:HQY - Free Report) - Stock analysts at Barrington Research upped their Q3 2026 earnings per share (EPS) estimates for HealthEquity in a note issued to investors on Wednesday, September 3rd. Barrington Research analyst A. Paris now forecasts that the company will post earnings per share of $0.73 for the quarter, up from their previous forecast of $0.72. Barrington Research has a "Outperform" rating and a $125.00 price objective on the stock. The consensus estimate for HealthEquity's current full-year earnings is $2.32 per share. Barrington Research also issued estimates for HealthEquity's FY2026 earnings at $3.26 EPS and FY2027 earnings at $3.84 EPS.

Other equities research analysts have also issued reports about the company. Bank of America increased their target price on HealthEquity from $110.00 to $125.00 and gave the stock a "buy" rating in a research report on Wednesday, June 4th. Royal Bank Of Canada increased their price target on HealthEquity from $109.00 to $110.00 and gave the stock an "outperform" rating in a research note on Wednesday, September 3rd. Jefferies Financial Group increased their price target on HealthEquity from $130.00 to $134.00 and gave the stock a "buy" rating in a research note on Wednesday, September 3rd. The Goldman Sachs Group increased their price target on HealthEquity from $94.00 to $104.00 and gave the stock a "neutral" rating in a research note on Wednesday, June 4th. Finally, JMP Securities increased their price target on HealthEquity from $110.00 to $117.00 and gave the stock a "market outperform" rating in a research note on Wednesday, June 4th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, HealthEquity currently has an average rating of "Buy" and a consensus target price of $119.77.

HealthEquity Price Performance

Shares of NASDAQ HQY opened at $91.48 on Monday. HealthEquity has a 1-year low of $74.07 and a 1-year high of $116.65. The company has a debt-to-equity ratio of 0.47, a current ratio of 4.23 and a quick ratio of 4.23. The business's fifty day moving average price is $94.37 and its two-hundred day moving average price is $94.86. The firm has a market capitalization of $7.88 billion, a PE ratio of 55.44, a P/E/G ratio of 1.30 and a beta of 0.50.

Insider Transactions at HealthEquity

In related news, EVP Michael Henry Fiore sold 1,794 shares of HealthEquity stock in a transaction dated Monday, July 7th. The stock was sold at an average price of $101.73, for a total transaction of $182,503.62. Following the transaction, the executive vice president directly owned 53,225 shares of the company's stock, valued at $5,414,579.25. The trade was a 3.26% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On HealthEquity

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in HQY. Invesco Ltd. boosted its stake in HealthEquity by 50.6% in the 1st quarter. Invesco Ltd. now owns 2,446,198 shares of the company's stock worth $216,171,000 after purchasing an additional 821,425 shares during the period. Norges Bank acquired a new position in HealthEquity in the 2nd quarter worth approximately $75,072,000. Westfield Capital Management Co. LP boosted its stake in HealthEquity by 124.6% in the 2nd quarter. Westfield Capital Management Co. LP now owns 1,265,208 shares of the company's stock worth $132,543,000 after purchasing an additional 701,819 shares during the period. AQR Capital Management LLC boosted its stake in HealthEquity by 148.5% in the 2nd quarter. AQR Capital Management LLC now owns 1,107,448 shares of the company's stock worth $116,016,000 after purchasing an additional 661,795 shares during the period. Finally, Nuveen LLC acquired a new position in HealthEquity in the 1st quarter worth approximately $53,076,000. Institutional investors and hedge funds own 99.55% of the company's stock.

HealthEquity Company Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.